Nothing Special   »   [go: up one dir, main page]

BRPI0520821A2 - fenofibrate pharmaceutical formulations with improved bioavailability - Google Patents

fenofibrate pharmaceutical formulations with improved bioavailability

Info

Publication number
BRPI0520821A2
BRPI0520821A2 BRPI0520821-1A BRPI0520821A BRPI0520821A2 BR PI0520821 A2 BRPI0520821 A2 BR PI0520821A2 BR PI0520821 A BRPI0520821 A BR PI0520821A BR PI0520821 A2 BRPI0520821 A2 BR PI0520821A2
Authority
BR
Brazil
Prior art keywords
fenofibrate
pharmaceutical formulations
improved bioavailability
polyethylene
fenofibrate pharmaceutical
Prior art date
Application number
BRPI0520821-1A
Other languages
Portuguese (pt)
Inventor
E Itzhak Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0520821A2 publication Critical patent/BRPI0520821A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULAçõES FARMACêUTICAS DE FENOFIBRATO COM BIODISPONIBILIDADE MELHORADA. São fornecidas composições farmacêuticas de fenofibrato, e formas de dosagem que as contém, que incluem fenofibrato, um polietileno glicol e um polietileno-propileno glicol; em que as composições são constituídas por sublimação de um portador sublimável com base em uma combinação de fenofibrato, o polietileno glicol e o polietileno-propíleno glicol com o portador sublimável, por exemplo, mentol.PHARMACEUTICAL FORMULATIONS OF PHENOPHYRATE WITH IMPROVED BIODAVAILABILITY. Fenofibrate pharmaceutical compositions and dosage forms containing them are provided, including fenofibrate, a polyethylene glycol and a polyethylene propylene glycol; wherein the compositions are sublimation of a sublimable carrier based on a combination of fenofibrate, polyethylene glycol and polyethylene propylene glycol with the sublimable carrier, e.g. menthol.

BRPI0520821-1A 2005-12-28 2005-12-28 fenofibrate pharmaceutical formulations with improved bioavailability BRPI0520821A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/047346 WO2007075171A1 (en) 2005-12-28 2005-12-28 Pharmaceutical formulations of fenofibrate having improved bioavailability

Publications (1)

Publication Number Publication Date
BRPI0520821A2 true BRPI0520821A2 (en) 2009-06-30

Family

ID=36499668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520821-1A BRPI0520821A2 (en) 2005-12-28 2005-12-28 fenofibrate pharmaceutical formulations with improved bioavailability

Country Status (7)

Country Link
JP (1) JP2009522258A (en)
CN (1) CN101351191A (en)
BR (1) BRPI0520821A2 (en)
CA (1) CA2634094A1 (en)
IL (1) IL192230A0 (en)
MX (1) MX2008008589A (en)
WO (1) WO2007075171A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2773588A1 (en) * 2009-09-09 2011-03-17 Bernard Charles Sherman Choline fenofibrate delayed release compositions
EP3998080A1 (en) * 2013-03-14 2022-05-18 Société des Produits Nestlé S.A. Manufacture of peanut formulations for oral desensitization
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
KR101850119B1 (en) 2015-11-11 2018-04-20 제이투에이치바이오텍 (주) Novel Fenofibric Acid Prodrugs with Improved Bioavailability
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
CN112618511A (en) * 2020-12-31 2021-04-09 辰欣药业股份有限公司 Prescription composition of fenofibrate capsule and preparation process thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
NZ525306A (en) * 2000-09-20 2004-11-26 Skyepharma Canada Inc Spray drying process and compositions of fenofibrate
CA2480377A1 (en) * 2002-03-26 2003-10-09 Teva Pharmaceutical Industries Ltd. Drug microparticles
KR20130103818A (en) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 A solid dosage form comprising a fibrate
WO2005034908A2 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin

Also Published As

Publication number Publication date
CA2634094A1 (en) 2007-07-05
IL192230A0 (en) 2008-12-29
CN101351191A (en) 2009-01-21
JP2009522258A (en) 2009-06-11
WO2007075171A1 (en) 2007-07-05
MX2008008589A (en) 2009-02-25

Similar Documents

Publication Publication Date Title
CL2007003244A1 (en) COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
GT199900203A (en) CELECOXIB COMPOSITIONS.
CL2007003686A1 (en) COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION.
RS50660B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
UY30759A1 (en) CHEMICAL COMPOUNDS
CL2004000930A1 (en) COMPOUND DERIVED FROM DEFINED FORMULA DIHYDROQUINAZOLINE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF VIRAL INFECTIONS; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND USE OF THE COMPOUND IN THE PREPARATION OF MEDICINES.
BRPI0814593A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2008003511A1 (en) Nucleotide derived compounds, hepatitis c virus ns5b polymerase inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
BRPI0620229A8 (en) formulation
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
CO6362017A2 (en) THERAPEUTIC ANTIVIRAL PEPTIDES
CL2008001024A1 (en) Phthalazinone derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cardiovascular diseases, parkinson's, inflammatory diseases, multiple sclerosis, cancer, among others
CL2007003540A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE SERINE PROTEASE OF HEPATITIS C; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
BRPI0520821A2 (en) fenofibrate pharmaceutical formulations with improved bioavailability
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2007001752A1 (en) Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.
CL2008002049A1 (en) Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
GT200800107A (en) ORAL FORMULATIONS THAT INCLUDE TIGECICLINE
CL2009000281A1 (en) Compounds derived from 5,6-dihydro-pyrrolo- [2,1-a] -isoquinolines and pyrrolo- [2,1-a] -isoquinolines; pharmaceutical composition comprising said compounds; and use for the treatment of fertility disorders.
NO20064808L (en) Oral matrix formulations with licarbazepine
CY1109209T1 (en) ANIONIC HYDROGEL MOTORS WITH PH-DEPENDENT MODIFIED RELEASE AS TRANSPORT OF MEDICINES
CL2008001990A1 (en) Compounds derived from substituted amino-quinazolines; pharmaceutical composition comprising said compound; and use of the compound for the treatment of Alzheimer's.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.